The cost of Mounjaro, the weight-loss medication produced by pharmaceutical giant Eli Lilly, will rise sharply in the UK from 1 September 2025, with some dosages expected to increase by as much as 170%.
The company says the price adjustment is intended to address “pricing inconsistencies compared with other developed countries” and to ensure all markets make fair contributions towards the funding of medical research.
The new prices will apply across all dosage strengths and will affect every regulated provider in the UK. Eli Lilly stressed that the decision is part of a wider industry-wide price alignment rather than a move made by individual distributors.
Mounjaro, also known by its generic name tirzepatide, has been in high demand in the UK since being approved for weight management in addition to its original use in treating type 2 diabetes. The price hike could affect thousands of patients who currently self-fund prescriptions for the drug through private providers.
